Ribosomal protein S6 promotes stem-like characters in glioma cells.
GBM stem-like cells
cancer stem cell
glioblastoma
ribosomal protein S6
ribosome
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
10
12
2019
revised:
18
03
2020
accepted:
20
03
2020
pubmed:
5
4
2020
medline:
20
6
2020
entrez:
5
4
2020
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM), a lethal brain tumor developing in the white matter of the adult brain, contains a small population of GBM stem cells (GSCs), which potentially cause chemotherapeutic resistance and tumor recurrence. However, the mechanisms underlying the pathogenesis and maintenance of GSCs remain largely unknown. A recent study reported that incorporation of ribosomes and ribosomal proteins into somatic cells promoted lineage trans-differentiation toward multipotency. This study aimed to investigate the mechanism underlying stemness acquisition in GBM cells by focusing on 40S ribosomal protein S6 (RPS6). RPS6 was significantly upregulated in high-grade glioma and localized at perivascular, perinecrotic, and border niches in GBM tissues. siRNA-mediated RPS6 knock-down significantly suppressed the characteristics of GSCs, including their tumorsphere potential and GSC marker expression; STAT3 was downregulated in GBM cells. RPS6 overexpression enhanced the tumorsphere potential of GSCs and these effects were attenuated by STAT3 inhibitor (AG490). Moreover, RPS6 expression was significantly correlated with SOX2 expression in different glioma grades. Immunohistochemistry data herein indicated that RPS6 was predominant in GSC niches, concurrent with the data from IVY GAP databases. Furthermore, RPS6 and other ribosomal proteins were upregulated in GSC-predominant areas in this database. The present results indicate that, in GSC niches, ribosomal proteins play crucial roles in the development and maintenance of GSCs and are clinically associated with chemoradioresistance and GBM recurrence.
Identifiants
pubmed: 32246865
doi: 10.1111/cas.14399
pmc: PMC7293102
doi:
Substances chimiques
Ribosomal Protein S6
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2041-2051Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18H02591
Organisme : Japan Society for the Promotion of Science
ID : 26713006
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
Nature. 2015 Apr 30;520(7549):640-5
pubmed: 25901680
Rare Dis. 2015 Apr 01;3(1):e1025185
pubmed: 26442198
J Pathol. 2000 Jun;191(2):181-6
pubmed: 10861579
Trends Cancer. 2015 Dec;1(4):252-265
pubmed: 27088132
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Cancer Cell. 2009 Feb 3;15(2):79-80
pubmed: 19185839
Trends Biochem Sci. 2006 Jun;31(6):342-8
pubmed: 16679021
Oncogene. 2018 Feb 22;37(8):1107-1118
pubmed: 29155422
Biochem Pharmacol. 2019 Jan;159:74-81
pubmed: 30468711
Lancet Oncol. 2014 Sep;15(10):1100-8
pubmed: 25163906
Oncotarget. 2015 Nov 17;6(36):38617-27
pubmed: 26415219
Oncotarget. 2017 Jan 31;8(5):8250-8263
pubmed: 28030813
J Cell Sci. 2005 Apr 1;118(Pt 7):1335-7
pubmed: 15788650
Cancer Sci. 2020 Jun;111(6):2041-2051
pubmed: 32246865
J Mol Cell Biol. 2015 Apr;7(2):92-104
pubmed: 25735597
Oncotarget. 2016 Jan 5;7(1):418-32
pubmed: 26506236
Stem Cells. 2009 Oct;27(10):2383-92
pubmed: 19658181
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Oncotarget. 2016 Sep 27;7(39):63226-63241
pubmed: 27557515
Hepatology. 2004 Jan;39(1):129-38
pubmed: 14752831
Oncol Lett. 2018 Oct;16(4):4095-4104
pubmed: 30250528
J Exp Clin Cancer Res. 2015 Oct 21;34:126
pubmed: 26490682
Br J Haematol. 2017 May;177(4):526-542
pubmed: 28211564
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
PLoS One. 2012;7(12):e51866
pubmed: 23300571
Oncotarget. 2014 Aug 15;5(15):6353-64
pubmed: 25071012
Annu Rev Biochem. 2004;73:657-704
pubmed: 15189156
BMC Cancer. 2006 Apr 11;6:91
pubmed: 16608517
PLoS One. 2016 Mar 17;11(3):e0151480
pubmed: 26985829
Cancer Res. 2006 Sep 15;66(18):9074-82
pubmed: 16982749
J Neurooncol. 2010 Dec;100(3):339-43
pubmed: 20455003
Mol Cell. 2009 Apr 10;34(1):3-11
pubmed: 19362532
Nat Rev Cancer. 2006 Jun;6(6):425-36
pubmed: 16723989
PLoS One. 2017 Aug 18;12(8):e0182705
pubmed: 28820908
Cancer Res. 2013 Mar 15;73(6):1811-20
pubmed: 23361300
Cancers (Basel). 2014 Sep 29;6(4):1986-2011
pubmed: 25268165
Nat Cell Biol. 2008 May;10(5):619-24
pubmed: 18425114
Dev Growth Differ. 2018 Jun;60(5):241-247
pubmed: 29845598
Nat Cell Biol. 2019 Aug;21(8):1003-1014
pubmed: 31371825
EBioMedicine. 2018 Apr;30:94-104
pubmed: 29559295
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Sci Rep. 2018 Jan 26;8(1):1634
pubmed: 29374279
Dev Growth Differ. 2015 May;57(4):305-12
pubmed: 25866152